Share Capital (Tables)
|
3 Months Ended |
Mar. 31, 2021 |
|---|
| Equity [Abstract] |
|
| Summary Of Warrants Activity |
The following table summarizes certain information in respect of the warrants for the Company’s shares:
|
|
|
|
|
|
|
|
|
| |
|
March 31, 2021 |
|
| |
|
Units |
|
|
Weighted Average Exercise Price
(C$)
|
|
Warrants outstanding as of December 31, 2020 |
|
|
49,236 |
|
|
$ |
4.06 |
|
|
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
|
(9,411 |
) |
|
|
2.52 |
|
| |
|
|
|
|
|
|
|
|
Warrants outstanding as of March 31, 2021 |
|
|
39,825 |
|
|
$ |
4.24 |
|
| |
|
|
|
|
|
|
|
|
|
| Summary Of Assumptions Used To Record Fair Value of Warrants |
As of March 31, 2021 and December 31, 2020, warrants classified as derivative liabilities in the unaudited interim condensed consolidated balance sheet were revalued, with the following inputs:
|
|
|
|
|
|
|
|
|
| |
|
March 31, 2021 |
|
|
December 31, 2020 |
|
|
|
|
0.2 |
% |
|
|
0.2 |
% |
|
|
|
0.0 |
% |
|
|
0.0 |
% |
|
|
|
139.0 - 209.6 |
% |
|
|
148.0 - 251.1 |
% |
|
| Schedule Of Warrants Outstanding |
Full share equivalent warrants outstanding and exercisable are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
March 31, 2021 |
|
|
December 31, 2020 |
|
|
|
Number
Outstanding |
|
|
Weighted Average
Exercise Price (C$) |
|
|
Number
Outstanding |
|
|
Weighted Average
Exercise Price (C$) |
|
|
|
|
17,185 |
|
|
$ |
5.16 |
|
|
|
26,596 |
|
|
$ |
4.37 |
|
|
|
|
20,855 |
|
|
|
3.44 |
|
|
|
20,855 |
|
|
|
3.62 |
|
|
|
|
1,785 |
|
|
|
4.57 |
|
|
|
1,785 |
|
|
|
4.57 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39,825 |
|
|
$ |
4.24 |
|
|
|
49,236 |
|
|
$ |
4.06 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Summary Of Potentially Dilutive Securities |
The following table summarizes potentially dilutive securities, and the resulting common share equivalents outstanding as of March 31, 2021:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,825 |
|
|
|
11,510 |
|
|
|
|
39,825 |
|
|
|
49,236 |
|
|
|
|
46,458 |
|
|
|
46,458 |
|
|
|
|
10,135 |
|
|
|
10,135 |
|
MPX dilutive instruments (1)
|
|
|
408 |
|
|
|
408 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
* |
Total potentially dilutive securities does not include the shares that would potentially be issued upon conversion of the accrued interest on the Company’s long-term debt. As of March 31, 2021, this would amount into 10.1 million common shares (December 31, 2020 – 8.0 million common shares). |
(1) |
Prior to the MPX Acquisition, MPX had instruments outstanding that were potentially dilutive and as a result of the MPX Acquisition, the Company assumed certain of these instruments. |
|
| Summary Of Option Activity |
The following table summarizes certain information in respect of option activity under the Company’s stock option plan:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
March 31, 2021 |
|
|
December 31, 2020 |
|
| |
|
Units |
|
|
Weighted
Average
Exercise Price
(C$) |
|
|
Weighted
Average
Contractual
Life |
|
|
Units |
|
|
Weighted
Average
Exercise
Price
(C$) |
|
|
Weighted
Average
Contractual
Life |
|
Options outstanding, beginning |
|
|
11,510 |
|
|
$ |
4.86 |
|
|
|
— |
|
|
|
19,578 |
|
|
$ |
4.80 |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
135 |
|
|
|
0.82 |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
(685 |
) |
|
|
4.09 |
|
|
|
— |
|
|
|
(8,203 |
) |
|
|
4.99 |
|
|
|
— |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding, ending |
|
|
10,825 |
|
|
$ |
4.91 |
|
|
|
6.72 |
|
|
|
11,510 |
|
|
$ |
4.86 |
|
|
|
7.34 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|